Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Apr;60(4):301–304. doi: 10.1136/thx.2004.025411

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

J Vestbo 1, R Pauwels 1, J Anderson 1, P Jones 1, P Calverley 1, b on 1
PMCID: PMC1747357  PMID: 15790985

Abstract

Background: Combined treatment with inhaled corticosteroids and long acting ß2 agonists is approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is known about the onset of effect of the combination.

Methods: Data were used from 1465 patients with COPD entered into a large 1 year double blind trial with daily measurements of peak expiratory flow (PEF) and symptom scores.

Results: PEF was significantly higher after 1 day in patients treated with salmeterol 50 µg twice daily or the salmeterol/fluticasone propionate combination 50/500 µg twice daily than placebo. In patients treated with fluticasone propionate 500 µg twice daily alone, PEF differed from placebo after 2 days. The differences after 2 weeks compared with placebo were 16 l/min (95% confidence interval (CI) 11 to 21), 11 l/min (95% CI 6 to 16), and 27 l/min (95% CI 22 to 33) for salmeterol, fluticasone propionate, and the salmeterol/fluticasone propionate combination, respectively. For all treatments the effect on PEF after 2 weeks was comparable to that seen at the end of the study. The difference between the salmeterol/fluticasone propionate combination and placebo after 2 weeks as a percentage of baseline was similar for PEF and clinic forced expiratory volume in 1 second (FEV1). Differences in breathlessness scores were statistically significant after 1 day for the group treated with salmeterol alone and after 2 days for the combination group. The 2 week change in FEV1 was only partly indicative of a long term response in individual patients.

Conclusions: The effects of salmeterol and fluticasone propionate, alone or in combination, on PEF and breathlessness are seen within days and most of the obtainable effect on these parameters is reached within 2 weeks.

Full Text

The Full Text of this article is available as a PDF (80.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyd G., Morice A. H., Pounsford J. C., Siebert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997 Apr;10(4):815–821. [PubMed] [Google Scholar]
  2. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Calverley Peter, Pauwels Romain, Vestbo Jørgen, Jones Paul, Pride Neil, Gulsvik Amund, Anderson Julie, Maden Claire, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2. [DOI] [PubMed] [Google Scholar]
  4. Casaburi R., Mahler D. A., Jones P. W., Wanner A., San Pedro G., ZuWallack R. L., Menjoge S. S., Serby C. W., Witek T., Jr A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002 Feb;19(2):217–224. doi: 10.1183/09031936.02.00269802. [DOI] [PubMed] [Google Scholar]
  5. Cazzola M., Santus P., Di Marco F., Carlucci P., Mondoni M., Matera M. G., Centanni S. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther. 2004;17(3):121–125. doi: 10.1016/j.pupt.2004.01.001. [DOI] [PubMed] [Google Scholar]
  6. Dahl R., Greefhorst L. A., Nowak D., Nonikov V., Byrne A. M., Thomson M. H., Till D., Della Cioppa G., Formoterol in Chronic Obstructive Pulmonary Disease I Study Group Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):778–784. doi: 10.1164/ajrccm.164.5.2007006. [DOI] [PubMed] [Google Scholar]
  7. Di Marco F., Milic-Emili J., Boveri B., Carlucci P., Santus P., Casanova F., Cazzola M., Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003 Jan;21(1):86–94. doi: 10.1183/09031936.03.00020102. [DOI] [PubMed] [Google Scholar]
  8. Hansen E. F., Vestbo J., Phanareth K., Kok-Jensen A., Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):690–693. doi: 10.1164/ajrccm.163.3.2006120. [DOI] [PubMed] [Google Scholar]
  9. O'Donnell D. E., Voduc N., Fitzpatrick M., Webb K. A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004 Jul;24(1):86–94. doi: 10.1183/09031936.04.00072703. [DOI] [PubMed] [Google Scholar]
  10. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  11. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  12. Rennard S. I., Anderson W., ZuWallack R., Broughton J., Bailey W., Friedman M., Wisniewski M., Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Apr;163(5):1087–1092. doi: 10.1164/ajrccm.163.5.9903053. [DOI] [PubMed] [Google Scholar]
  13. Spencer S., Calverley P. M., Sherwood Burge P., Jones P. W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):122–128. doi: 10.1164/ajrccm.163.1.2005009. [DOI] [PubMed] [Google Scholar]
  14. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 Jan;21(1):74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  15. Ulrik C. S. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax. 1995 Jul;50(7):750–754. doi: 10.1136/thx.50.7.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  17. Vincken W., van Noord J. A., Greefhorst A. P. M., Bantje Th A., Kesten S., Korducki L., Cornelissen P. J. G., Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002 Feb;19(2):209–216. doi: 10.1183/09031936.02.00238702. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES